Assessment of diminished peristalsis using shakuyakukanzoto as premedication for endoscopic retrograde cholangiopancreatography

Assessment of diminished peristalsis using shakuyakukanzoto as premedication for endoscopic retrograde cholangiopancreatography - Shakuyakukanzoto for ERCP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011469

Enrollment

Registered

2013-11-30

Start date

2006-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for ERCP at Toyama University Hospital

Interventions

Shakuyakukanzoto solution was contained 5.0 g of Shakuyakukanzoto extract dissolved in 50 ml of warm water (36 degrees Celsius). As the premedication, the Shakuyakukanzoto solution was administered by

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients need ERCP examination.

Exclusion criteria

Exclusion criteria: (1) Inability to provide written informed consent; (2) Inability to access duodenal papilla endoscopically; (3) Patients with ischemic heart disease, prostatic hypertrophy or glaucoma; (4) Patients with acute pancreatitis; (5) Serum K level >5.0 mEq/L

Design outcomes

Primary

Measure	Time frame
Duodenal peristalsis stop rate after administration of Shyakuyakukanzoto	—

Secondary

Measure	Time frame
Measured a required time (RT) from administering premedication to diminished peristalsis and a peristalsis stop duration time (DT)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026